Alnylam Pharmaceuticals, Inc. (ALNY) Stock Price

ALNYStock

$237.10−47.58%52W

Market Cap$31.73B

P/E96.86x

PEG Ratio0.46

Div yield—

Beta0.25

ALNY Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-40.70%

Price vs S&P 500 (4W)6.07%

PEG Ratio0.46

VGM Score48.73

P/E Ratio (Annual)96.86x

P/CF (Annual)57.99x

Book Value / Share (Quarterly)$10.13

P/TBV (Annual)2.64x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)52.98%

Cash Flow / Share (Quarterly)$5.94

Price vs S&P 500 (YTD)-53.20%

Gross Margin (TTM)79.65%

Net Profit Margin (TTM)16.82%

EPS (TTM)$5.88

10-Day Avg Trading Volume1.66M

EPS Excl Extra (TTM)$5.88

Revenue Growth (5Y)49.77%

EPS (Annual)$2.33

ROI (Annual)9.00%

Gross Margin (Annual)81.64%

Net Profit Margin (5Y Avg)-47.61%

Cash / Share (Quarterly)$24.74

P/E Basic Excl Extra (TTM)37.61x

Revenue Growth QoQ (YoY)66.86%

P/E Normalized (Annual)96.86x

ROA (Last FY)6.32%

Revenue Growth TTM (YoY)95.14%

EBITD / Share (TTM)$7.36

ROE (5Y Avg)-133.18%

Operating Margin (TTM)19.93%

Cash Flow / Share (Annual)$3.52

P/B Ratio22.44x

P/B Ratio (Quarterly)29.68x

Net Income / Employee (Annual)$125,500

EV / Revenue (TTM)6.54x

Net Interest Coverage (TTM)3.25x

ROA (TTM)15.76%

EV / EBITDA (TTM)31.04x

EPS Incl Extra (Annual)$2.33

Current Ratio (Annual)2.76x

Quick Ratio (Quarterly)2.79x

3-Month Avg Trading Volume1.53M

52-Week Price Return-47.58%

EV / Free Cash Flow (Annual)67.50x

P/E Incl Extra (TTM)37.61x

Revenue / Employee (TTM)$1,921,700

Tangible BV / Share (Quarterly)$3.38

P/S Ratio (Annual)8.18x

Asset Turnover (Annual)0.75x

52-Week High$495.55

Operating Margin (5Y Avg)-35.59%

EPS Excl Extra (Annual)$2.33

CapEx CAGR (5Y)-3.57%

Tangible BV CAGR (5Y)21.68%

26-Week Price Return-28.77%

Quick Ratio (Annual)2.51x

13-Week Price Return-22.28%

Total Debt / Equity (Annual)3.42x

Current Ratio (Quarterly)3.05x

Enterprise Value$31.41B

Revenue / Share Growth (5Y)45.11%

Asset Turnover (TTM)0.94x

Book Value / Share Growth (5Y)-14.26%

Revenue / Employee (Annual)$1,485,600

Inventory Turnover (Annual)8.46x

Pretax Margin (Annual)8.70%

Cash / Share (Annual)$21.97

3-Month Return Std Dev69.69%

Gross Margin (5Y Avg)83.48%

Net Income / Employee (TTM)$323,200

ROE (Last FY)39.76%

Net Interest Coverage (Annual)4.61x

EPS Basic Excl Extra (Annual)$2.33

P/FCF (TTM)38.28x

Receivables Turnover (TTM)7.04x

EV / Free Cash Flow (TTM)39.57x

Total Debt / Equity (Quarterly)2.02x

EPS Incl Extra (TTM)$5.88

Receivables Turnover (Annual)7.20x

ROI (TTM)22.93%

P/S Ratio (TTM)6.33x

Pretax Margin (5Y Avg)-48.27%

Revenue / Share (Annual)$27.58

Tangible BV / Share (Annual)$3.73

Forward P/E22.49x

Price vs S&P 500 (52W)-66.14%

P/E Ratio (TTM)37.61x

Year-to-Date Return-40.37%

5-Day Price Return0.46%

EPS Normalized (Annual)$2.33

ROA (5Y Avg)-13.41%

Net Profit Margin (Annual)8.45%

Month-to-Date Return15.37%

Cash Flow / Share (TTM)$-3.62

EBITD / Share (Annual)$3.82

Operating Margin (Annual)12.36%

LT Debt / Equity (Annual)3.14x

P/CF (TTM)34.31x

ROI (5Y Avg)-40.42%

P/E Excl Extra (TTM)37.61x

LT Debt / Equity (Quarterly)1.83x

EPS Basic Excl Extra (TTM)$5.88

P/TBV (Quarterly)5.56x

P/B Ratio (Annual)66.57x

Inventory Turnover (TTM)11.58x

Pretax Margin (TTM)16.64%

Book Value / Share (Annual)$5.96

Price vs S&P 500 (13W)-24.23%

Beta0.25x

P/FCF (Annual)65.30x

Revenue / Share (TTM)$34.74

ROE (TTM)93.61%

52-Week Low$197.81

vGradeD

gGradeA

mGradeD

vgmGradeC

ALNY Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Jul 30, 2026	$2.14	$1.84	-14.21%(-$0.30)
Q1 2026	Apr 30, 2026	$1.47	$1.99	+35.30%(+$0.52)
Q4 2025	Feb 12, 2026	$1.50	$1.25	-16.50%(-$0.25)
Q3 2025	Oct 30, 2025	$1.75	$2.90	+66.12%(+$1.15)
Q2 2025	Jul 31, 2025	$0.15	$0.32	+119.58%(+$0.17)

ALNY Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

3.94

3.95

3.97

4.00

Industry Peers — Pharmaceuticals(570)

Symbol	Value Score	Growth Score	Momentum Score	Price
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$237.10
LLYEli Lilly & Co.	D	B	C	$1174.61
JNJJohnson & Johnson	D	C	B	$268.04
ABBVABBVIE INC.	D	C	B	$255.48
MRKMerck & Co., Inc.	D	C	B	$148.35
NVSNovartis AG	C	C	C	$153.81
AZNAstraZeneca PLC	C	B	C	$162.70
NVONovo-Nordisk A/S	B	C	C	$45.61
ABTAbbott Laboratories	C	C	C	$112.47
PFEPfizer Inc.	C	D	B	$27.96
VRTXVertex Pharmaceuticals Inc	D	C	B	$541.69
BMYBristol-Myers Squibb Co.	B	B	B	$66.58
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$44.82
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$50.82
REGNRegeneron Pharmaceuticals Inc	C	C	B	$794.19
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	B	$18.03
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$36.44
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	$366.73
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$60.85
ZTSZOETIS INC.	C	C	D	$77.34
INSMInsmed, Inc.	F	A	C	$118.54
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$34.71
UTHRUnited Therapeutics Corp	C	C	B	$515.46
GMABGenmab A/S ADS	C	C	B	$33.23
VTRSViatris Inc. Common Stock	B	C	B	$16.34
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$247.91
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$244.54
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$76.60
BMRNBioMarin Pharmaceuticals Inc	C	C	B	$64.67
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	B	$533.76
CORTCorcept Therapeutics Inc.	F	C	B	$113.88
ELANElanco Animal Health Incorporated Common Stock	C	B	C	$24.11
ARWRArrowhead Research Corporation	D	A	B	$84.91
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.73
AXSMAxsome Therapeutics, Inc	D	B	C	$199.02
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.18
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$61.05
CYTKCytokinetics Inc.	F	D	C	$72.09
ABVXAbivax SA American Depositary Shares	—	—	C	$113.35
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$344.75
PTGXProtagonist Therapeutics, Inc	F	B	B	$144.33
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.84
TGTXTG Therapeutics, Inc.	D	B	B	$53.93
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	$90.36
ALKSAlkermes Inc. plc	D	C	B	$47.41
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$107.17
ERASErasca, Inc. Common Stock	—	—	A	$18.03
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$65.67
BLTEBelite Bio, Inc American Depositary Shares	—	—	C	$151.72
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	C	C	B	$17.54

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals is a leader in RNA interference (RNAi) therapeutics with five FDA-approved drugs generating revenue across rare genetic diseases and cardio-metabolic indications. The company has an expanding pipeline in genetic medicines, hepatic infectious diseases, and CNS/ocular diseases, with multiple programs in clinical development. Partnership upfront fees and upcoming milestone and royalty payments from collaborations provide additional cash generation and revenue diversification beyond its commercial portfolio.